-
1
-
-
84900834246
-
-
The global burden. Brussels, Belgium: International Diabetes Federation [Last accessed 29 October 2013]
-
The global burden. Brussels, Belgium: International Diabetes Federation, 2012. Available at: http://www.idf.org/diabetesatlas/5e/the-global-burden [Last accessed 29 October 2013]
-
(2012)
-
-
-
2
-
-
84900827235
-
-
The World Health Report Geneva Switzerland: World Health Organization 2002 [Last accessed 29 October 2013]
-
The World Health Report 2002. Geneva, Switzerland: World Health Organization, 2002. Available at: http://www.who.int/whr/2002/en/whr02-en.pdf [Last accessed 29 October 2013]
-
(2002)
-
-
-
3
-
-
84900806311
-
-
Outline for the Results of the National Health and Nutrition Survey Japan Tokyo, Japan: Ministry of Health, Labour and Welfare 2007 [Last accessed 29 October 2013]
-
Outline for the Results of the National Health and Nutrition Survey Japan, 2007. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2007. Available at: http://www.nih.go.jp/eiken/english/research/pdf/nhns2007.pdf [Last accessed 29 October 2013]
-
(2007)
-
-
-
4
-
-
3042672692
-
Insulin secretion and insulin sensitivity at different stages of glucose tolerance: A cross-sectional study of Japanese type 2 diabetes
-
Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004;53:831-5
-
(2004)
Metabolism
, vol.53
, pp. 831-835
-
-
Fukushima, M.1
Usami, M.2
Ikeda, M.3
-
5
-
-
3042569974
-
Primacy of beta-cell dysfunction in the development of hyperglycemia: A study in the Japanese general population
-
Katakura M, Komatsu M, Sato Y, et al. Primacy of beta-cell dysfunction in the development of hyperglycemia: a study in the Japanese general population. Metabolism 2004;53:949-53
-
(2004)
Metabolism
, vol.53
, pp. 949-953
-
-
Katakura, M.1
Komatsu, M.2
Sato, Y.3
-
6
-
-
79959449171
-
Body mass index and diabetes in Asia: A cross-sectional pooled analysis of 900, 000 individuals in the Asia cohort consortium
-
Boffetta P, McLerran D, Chen Y, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900, 000 individuals in the Asia cohort consortium. PLoS One 2011;6:e19930
-
(2011)
PLoS One
, vol.6
-
-
Boffetta, P.1
McLerran, D.2
Chen, Y.3
-
7
-
-
67651146970
-
-
Tokyo, Japan: Japan Diabetes Society [Last accessed 29 October 2013]
-
Treatment Guide for Diabetes, 2007. Tokyo, Japan: Japan Diabetes Society; 2007. Available at: http://www.jds.or.jp/modules/en/index.php?content- id35 [Last accessed 29 October 2013]
-
(2007)
Treatment Guide for Diabetes, 2007
-
-
-
8
-
-
0037045845
-
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study
-
Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
-
(2002)
Lancet
, vol.359
, pp. 824-830
-
-
Zander, M.1
Madsbad, S.2
Madsen, J.L.3
-
9
-
-
0036828227
-
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
-
Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408
-
(2002)
Endocrinology
, vol.143
, pp. 4397-4408
-
-
Farilla, L.1
Hui, H.2
Bertolotto, C.3
-
10
-
-
0029907680
-
Effects of subcutaneous gluca-gon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
-
Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous gluca-gon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53
-
(1996)
Diabetologia
, vol.39
, pp. 1546-1553
-
-
Nauck, M.A.1
Wollschlager, D.2
Werner, J.3
-
11
-
-
78650903000
-
GIP and GLP-1, the two incretin hormones: Similarities and differences
-
Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010;1:8-23
-
(2010)
J Diabetes Investig
, vol.1
, pp. 8-23
-
-
Seino, Y.1
Fukushima, M.2
Yabe, D.3
-
12
-
-
84878360808
-
Glucose-dependent insulinotropic polypeptide and gluca-gon-like peptide-1: Incretin actions beyond the pancreas
-
Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and gluca-gon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
-
(2013)
J Diabetes Investig
, vol.4
, pp. 108-130
-
-
Seino, Y.1
Yabe, D.2
-
13
-
-
0037241085
-
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
-
Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 220-224
-
-
Vilsboll, T.1
Agerso, H.2
Krarup, T.3
-
14
-
-
0027215348
-
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide his-tidine methionine and is responsible for their degradation in human serum
-
Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide his-tidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
-
(1993)
Eur J Biochem
, vol.214
, pp. 829-835
-
-
Mentlein, R.1
Gallwitz, B.2
Schmidt, W.E.3
-
15
-
-
84900818947
-
-
Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc. [Last accessed 29 October 2013]
-
Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc., 2011. Available at: http://documents.byetta.com/Byetta-PI.pdf [Last accessed 29 October 2013]
-
(2011)
-
-
-
16
-
-
77953744676
-
-
Plainsboro NJ: Novo Nordisk Inc. [Last accessed 29 October 2013]
-
Victoza [package insert]. Plainsboro NJ: Novo Nordisk Inc. 2010. Available at: http://www.novo-pi.com/victoza.pdf [Last accessed 29 October 2013]
-
(2010)
Victoza [Package Insert]
-
-
-
17
-
-
79953170013
-
Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
-
Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 2010;1:56-9
-
(2010)
J Diabetes Investig
, vol.1
, pp. 56-59
-
-
Yabe, D.1
Kuroe, A.2
Lee, S.3
-
18
-
-
79956200849
-
Albiglutide, Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes
-
Rosenstock J, Stewart MW. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Future 2010;35:701-12
-
(2010)
Drugs Future
, vol.35
, pp. 701-712
-
-
Rosenstock, J.1
Stewart, M.W.2
-
19
-
-
70349664297
-
Potential of albiglutide, a long-Acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
-
Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-Acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6
-
(2009)
Diabetes Care
, vol.32
, pp. 1880-1886
-
-
Rosenstock, J.1
Reusch, J.2
Bush, M.3
-
20
-
-
57349168543
-
Pharmacodynamics, pharma-cokinetics, safety, and tolerability of albiglutide, a long-Acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes
-
Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharma-cokinetics, safety, and tolerability of albiglutide, a long-Acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810-17
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 4810-4817
-
-
Matthews, J.E.1
Stewart, M.W.2
De Boever, E.H.3
-
21
-
-
72549107810
-
Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-Acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
-
Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-Acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25:3049-57
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 3049-3057
-
-
Seino, Y.1
Nakajima, H.2
Miyahara, H.3
-
22
-
-
79251476847
-
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus
-
The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus
-
The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010; 1: 212-28
-
(2010)
J Diabetes Investig
, vol.1
, pp. 212-228
-
-
Seino, Y.1
Nanjo, K.2
-
23
-
-
0037414781
-
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis
-
Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471-8
-
(2003)
J Biol Chem
, vol.278
, pp. 471-478
-
-
Li, Y.1
Hansotia, T.2
Yusta, B.3
-
24
-
-
84862299162
-
Effects of glucagon-like peptide-1 receptor agonists on body weight: A meta-Analysis
-
Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-Analysis. Exp Diabetes Res 2012;2012:672658
-
(2012)
Exp Diabetes Res
, vol.2012
, pp. 672658
-
-
Monami, M.1
Dicembrini, I.2
Marchionni, N.3
-
25
-
-
84859003663
-
Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-Analyses of randomised controlled trials
-
Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-Analyses of randomised controlled trials. BMJ 2012;344:d7771
-
(2012)
BMJ
, vol.344
-
-
Vilsboll, T.1
Christensen, M.2
Junker, A.E.3
-
26
-
-
84856000294
-
GLP-1, the gut-brain, and brain-periphery axes
-
Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011;8:418-31
-
(2011)
Rev Diabet Stud
, vol.8
, pp. 418-431
-
-
Cabou, C.1
Burcelin, R.2
-
27
-
-
80053617078
-
Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial
-
Seino Y, Rasmussen MF, Nishida T, et al. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Investig 2011;2:280-6
-
(2011)
J Diabetes Investig
, vol.2
, pp. 280-286
-
-
Seino, Y.1
Rasmussen, M.F.2
Nishida, T.3
-
28
-
-
34249869806
-
Liraglutide, a long-Acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
-
Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-Acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
-
(2007)
Diabetes Care
, vol.30
, pp. 1608-1610
-
-
Vilsboll, T.1
Zdravkovic, M.2
Le-Thi, T.3
-
29
-
-
84857045922
-
The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
-
Kanoski SE, Rupprecht LE, Fortin SM, et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012;62:1916-27
-
(2012)
Neuropharmacology
, vol.62
, pp. 1916-1927
-
-
Kanoski, S.E.1
Rupprecht, L.E.2
Fortin, S.M.3
-
30
-
-
77950228684
-
Glucagon-like pep-tide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
-
Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like pep-tide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151: 1473-86
-
(2010)
Endocrinology
, vol.151
, pp. 1473-1486
-
-
Knudsen, L.B.1
Madsen, L.W.2
Andersen, S.3
-
31
-
-
67649304917
-
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exena-tide or sitagliptin compared to metformin or glyburide
-
Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exena-tide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 1019-1027
-
-
Dore, D.D.1
Seeger, J.D.2
Arnold Chan, K.3
-
32
-
-
84900833895
-
-
Guidance for Industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research [Last accessed 29 October 2013]
-
Guidance for Industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2008. Available at: http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformation/guidance/ucm071627.pdf [Last accessed 29 October 2013]
-
(2008)
-
-
|